With Its Third Biologic, India’s Glenmark Claims Success With Anti-OX40 MAb
This article was originally published in PharmAsia News
Glenmark’s Swiss research center is bulking up its pipeline as its third discovery advances to the clinic.
You may also be interested in...
Sanofi Continues Search For Novel Compounds In Asia, Inking Deal With India's Glenmark For Phase I Biologic
MUMBAI - Continuing with its strategy to aggressively pursue in-licensing of novel R&D from Asia, French drug maker Sanofi signed a deal with India's Glenmark Pharmaceuticals Ltd. for the development and commercialization of GBR 500 - a novel monoclonal antibody for the treatment of Crohn's disease and other inflammatory conditions. The present market size for Crohn's disease is $2-3 billion, executives at Glenmark said, terming the first ever deal for a biological candidate from India as "landmark.
"We Have Gone Through Hardships But Our Passion Remains High," Says Glenn Saldanha, Managing Director, Glenmark Pharma: An Interview With PharmAsia News (Part 1 of 2)
Glenn Saldanha, Managing Director, Glenmark Pharmaceuticals has been speaking about discovery research in India for more than a decade but his critics from bigger companies played down those efforts as high decibel talk, over-ambitious thoughts and a few even called them day dreaming moves. But five out-licensing deals in seven years with companies like Eli Lilly, Merck Serono and Sanofi-Aventis have transformed the way Glenmark Pharma is seen by the world today. Saldanha recalls the early days of his programs, the learning from his research partners and what his pipeline of drugs hold for the future in an exclusive interview with PharmAsia News' India bureau.
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.